Adults over 65 have been the fastest-growing group of new cannabis users in several markets. They are also the group with the most medications, the most comorbidities, the highest fall risk, and the least research specific to them.
That combination deserves more careful treatment than it usually gets.
Not medical advice. TruMo Analytics is a cannabis testing laboratory, not a healthcare provider. If you are an older adult or veteran considering medical cannabis — particularly alongside existing medications — this is a conversation for a clinician who knows your full history.
Why Age Changes the Calculation
Several physiological changes matter.
Metabolism slows. Liver and kidney function decline with age, so drugs — including cannabinoids — are cleared more slowly. Effects last longer and accumulate more readily. Starting doses appropriate for a younger adult can be too high.
Body composition changes. Increased body fat relative to lean mass affects how fat-soluble compounds like cannabinoids distribute and how long they persist.
Polypharmacy. Older adults commonly take several medications, sometimes many. Every one is a potential interaction, and the risk compounds. This is the single most important consideration in this group — see cannabis and drug interactions.
Fall risk. Cannabis affects balance, coordination and blood pressure, including orthostatic hypotension. In a population where a fall can be a catastrophic event, sedation and dizziness are not minor side effects.
Cardiovascular sensitivity. THC raises heart rate, which is a more significant consideration where cardiac disease is present.
Cognitive effects. Acute cannabis effects on memory and attention may be more pronounced, and harder to distinguish from other causes, in older adults.
What the Research Says About This Group
Less than it should. Older adults have historically been underrepresented in cannabis trials, so much of what is known is extrapolated from younger populations.
Available evidence suggests older adults may be more sensitive to adverse effects — sedation, dizziness, cognitive effects — at doses that younger adults tolerate. Observational studies report symptom improvement for pain and sleep in some older patients. Dosing that starts low and increases slowly appears better tolerated, which is the general principle but matters more here.
The absence of good evidence is not evidence of harm. It is a reason for caution and monitoring rather than confidence.
Veterans
Veterans use medical cannabis at higher rates than the general population, largely for chronic pain, PTSD and sleep.
Several considerations are specific to this group.
VA care. Because cannabis remains federally controlled, VA providers cannot recommend it or complete state programme paperwork. However, VA policy is that veterans should not be denied care for using cannabis, and providers can discuss it. Being open with your VA clinician is important — they need to know for interaction and treatment purposes, and it does not jeopardise your care.
PTSD evidence. Widely used for this and less well supported than the usage rate implies. Controlled trials have produced mixed results, with sleep and nightmares the more supportable claim than core symptom improvement. See cannabis and mental health.
Medication interactions. Veterans are frequently on psychiatric medications, pain medications, or both — precisely the categories where interaction risk is highest.
Oklahoma access. Oklahoma’s programme applies a reduced application fee for applicants providing acceptable proof of 100% disabled veteran status. See how to get a medical marijuana card in Oklahoma.
Palliative and End-of-Life Care
This is a distinct context where the usual calculations change.
In palliative care, the goal is comfort rather than cure, and the balance between symptom relief and long-term risk shifts accordingly. Cannabis is used in this setting for pain, nausea, appetite loss, anxiety and sleep — often several at once, which is part of its appeal where the alternative is multiple additional medications.
The evidence is limited but the clinical rationale is more straightforward: side effects that would matter over decades matter less over weeks, and quality of life is the explicit measure.
What still matters is coordination. Palliative patients are typically on complex regimens including opioids and sedatives, where additive effects are real. This should be managed by the palliative team rather than added independently.
Practical Guidance
Start much lower than standard guidance. If a typical starting dose is 2.5 mg THC, half that is a reasonable starting point for an older adult with no tolerance. Increase more slowly than you would expect to need to.
Consider CBD-dominant products first. Non-intoxicating, less likely to cause dizziness or confusion. Note that CBD carries its own interaction profile, which is not a small consideration in this group.
Take a full medication list to the appointment. Prescriptions, over-the-counter medicines, supplements, everything. A pharmacist review is worth arranging.
Prefer measurable formats. Capsules and tinctures allow exact, repeatable doses. Flower does not. See forms of medical cannabis.
First doses at home, seated, with someone present. Fall risk is the most immediate practical hazard.
Take products for someone immunocompromised seriously. Older adults, cancer patients and transplant recipients face the highest risk from fungal contamination. Verified contaminant testing is not optional here — see the risks of untested cannabis products and how to choose tested products.
Involve family or carers. Someone who can notice increased confusion, unsteadiness or sedation is a genuine safety measure.
Why Product Verification Matters More Here
An inaccurate dose is a bigger problem for a patient who is more sensitive, on more medications and at higher fall risk.
If a labelled 5 mg capsule actually contains 12 mg, the consequences for an 80-year-old on antihypertensives and a sedative are materially different from the consequences for a healthy 30-year-old.
That is the practical link between laboratory testing and this population specifically. Verified potency, verified homogeneity in infused products, and a complete contaminant panel are what make careful dosing possible at all.
Check that the batch on the packaging matches the certificate, that the date is current, and that contaminants were tested and not just potency. It takes under a minute and it matters more for this group than for any other.